diff --git a/inbox/queue/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md b/inbox/queue/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md
index 0cbd4abe..2e1a9d2d 100644
--- a/inbox/queue/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md
+++ b/inbox/queue/2026-03-30-jacc-cardiometabolic-treatment-control-rates-1999-2023.md
@@ -42,8 +42,8 @@ Despite the availability of effective generic medications for all three conditio
 **KB connections:**
 - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] — this is the clinical-trial-level evidence for the 80-90% claim: 76.6% treatment failure despite effective drugs
 - [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] — the SDOH screening/action gap explains why these patients aren't being treated at the SDOH level
-- [[social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day]] — social isolation → adherence failure → treatment non-control
-- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways]] — food environment → persistent hypertension despite medication
+- social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day — social isolation → adherence failure → treatment non-control
+- Big Food companies engineer addictive products by hacking evolutionary reward pathways — food environment → persistent hypertension despite medication
 
 **Extraction hints:**
 - "Only 23.4% of treated US hypertensives achieved blood pressure control in 2021-2023, and the proportion simultaneously controlling hypertension, diabetes, and hyperlipidemia never exceeded 30% between 1999-2023, demonstrating that pharmacological availability is not the binding constraint in cardiometabolic disease management"